Oliver Heard
Research Subjects
Oliver Heard has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Anna Sanigorska
HCD Economics Knutsford UK
2 shared publicationsCheryl Jones
HCD Economics Knutsford UK
2 shared publicationsHeena Howitt
Takeda UK Ltd. London UK
2 shared publications- Mike Laffan
Centre for Haematology, Department of Immunology and Inflammation Imperial College London London UK
2 shared publications Rosa Willock
HCD Economics Knutsford UK
2 shared publicationsSarah Brighton
HCD Economics Knutsford UK
2 shared publications
Latest Publications
- Open Access
- 10 May 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 248-256
Clinical burden and healthcare resource use of congenital thrombotic thrombocytopenic purpura in England: A linked primary and secondary care data analysis
Summary: Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra rare haematological disorder. This study aimed to estimate the clinical burden, healthcare resource use (HCRU) and associated costs of cTTP in England using primary and secondary care data. A retrospective cohort study was undertaken using the Clinical Practice Research Datalink (Aurum) linked to Hospital Episode Statistics data. The study period was from 01 January 2000 to 31 December 2019. Patients with cTTP were identified using an algorithm and matched 1:2 to patients without thrombotic thrombocytopenic purpura (TTP) (non‐TTP cohort) to contextualise the findings. A total of 36 cTTP patients were identified. The mean follow‐up for cTTP patients was 4.4 and 5.7 years in primary and secondary care, respectively, and 4.9 and 5.8 years for the non‐TTP cohort. Of the 36 patients, 38.9% experienced an acute episode and 19.4% experienced an organ damage event during follow‐up. HCRU (including inpatient admission, outpatient appointments and primary care appointments) was higher in the cTTP cohort relative to the non‐TTP cohort. The average yearly cost of healthcare for a cTTP patient was £6155, relative to £858 in the non‐TTP cohort. This study demonstrates the high clinical and economic burden of cTTP and provides evidence to inform healthcare planning.
- 10 May 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 248-256
Open AccessClinical burden and healthcare resource use of congenital thrombotic thrombocytopenic purpura in England: A linked primary and secondary care data analysis
Summary: Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra rare haematological disorder. This study aimed to estimate the clinical burden, healthcare resource use (HCRU) and associated costs of cTTP in England using primary and secondary care data. A retrospective cohort study was undertaken using the Clinical Practice Research Datalink (Aurum) linked to Hospital Episode Statistics data. The study period was from 01 January 2000 to 31 December 2019. Patients with cTTP were identified using an algorithm and matched 1:2 to patients without thrombotic thrombocytopenic purpura (TTP) (non‐TTP cohort) to contextualise the findings. A total of 36 cTTP patients were identified. The mean follow‐up for cTTP patients was 4.4 and 5.7 years in primary and secondary care, respectively, and 4.9 and 5.8 years for the non‐TTP cohort. Of the 36 patients, 38.9% experienced an acute episode and 19.4% experienced an organ damage event during follow‐up. HCRU (including inpatient admission, outpatient appointments and primary care appointments) was higher in the cTTP cohort relative to the non‐TTP cohort. The average yearly cost of healthcare for a cTTP patient was £6155, relative to £858 in the non‐TTP cohort. This study demonstrates the high clinical and economic burden of cTTP and provides evidence to inform healthcare planning.
- Open Access
- 11 October 2025
- Published by Wiley in European Journal of Haematology
- Vol. 116 (1) , 75-84
Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom
Objectives: We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom. Methods: Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the prevention/treatment of surgery‐related bleeds, or the on‐demand treatment of spontaneous/traumatic bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD‐related HCRU data associated with the prevention/treatment of surgery‐related bleeds were collected at first (index) event, for 12 months pre‐index and 3–12 months post‐index. Results: Twenty patients (55.0% female, 90.0% White/Caucasian, mean age 56.7 years) received rVWF to prevent/treat surgery‐related bleeds at index: normal haemostasis following abnormal bleeding was achieved for all applicable bleeds with limited requirement for additional treatments. Only four patients (all VWD type 2) received exogenous factor VIII in addition to rVWF at index. There were no treatment switches and no likely treatment‐related complications. Physician‐rated treatment satisfaction was ‘excellent’ (36.7%) or ‘good’ (63.3%) for all rVWF‐treated surgery‐related bleeds ( n = 30). Conclusions: Results support the effectiveness and safety profile of rVWF in a surgical setting in adults with VWD, supplementing the growing body of evidence for rVWF.
- 11 October 2025
- Published by Wiley in European Journal of Haematology
- Vol. 116 (1) , 75-84
Open AccessOutcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom
Objectives: We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom. Methods: Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the prevention/treatment of surgery‐related bleeds, or the on‐demand treatment of spontaneous/traumatic bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD‐related HCRU data associated with the prevention/treatment of surgery‐related bleeds were collected at first (index) event, for 12 months pre‐index and 3–12 months post‐index. Results: Twenty patients (55.0% female, 90.0% White/Caucasian, mean age 56.7 years) received rVWF to prevent/treat surgery‐related bleeds at index: normal haemostasis following abnormal bleeding was achieved for all applicable bleeds with limited requirement for additional treatments. Only four patients (all VWD type 2) received exogenous factor VIII in addition to rVWF at index. There were no treatment switches and no likely treatment‐related complications. Physician‐rated treatment satisfaction was ‘excellent’ (36.7%) or ‘good’ (63.3%) for all rVWF‐treated surgery‐related bleeds ( n = 30). Conclusions: Results support the effectiveness and safety profile of rVWF in a surgical setting in adults with VWD, supplementing the growing body of evidence for rVWF.
- Open Access
- 10 October 2025
- Published by Wiley in European Journal of Haematology
- Vol. 116 (1) , 66-74
Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom
Objectives: We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) treated on demand with recombinant von Willebrand factor (rVWF) in the United Kingdom. Methods: Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the on‐demand treatment of spontaneous/traumatic bleeds, or the prevention/treatment of surgical bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD‐related HCRU data associated with the on‐demand treatment of all recorded bleeds were collected at first (index) treatment, for 12 months pre‐index and 3–12 months post‐index. Results: Twelve patients (91.7% female and White/Caucasian, mean age 34.2 years) were treated on demand with rVWF at index: bleed resolution was achieved for all bleeds with limited requirement for additional treatments, no treatment switches, and no complications reported. Physician‐rated treatment satisfaction was ‘excellent’ (82.6%) or ‘good’ (17.4%) for all recorded on‐demand rVWF‐treated bleeds ( n = 23). Patients receiving any on‐demand treatment required an inpatient admission and ≥ 1 outpatient visit in 33.7% and 66.7% of cases, respectively. Conclusions: Results support the effectiveness and safety profile of on‐demand rVWF treatment for spontaneous/traumatic bleeds in adults with VWD, adding to the growing body of evidence for rVWF.
- 10 October 2025
- Published by Wiley in European Journal of Haematology
- Vol. 116 (1) , 66-74
Open AccessOutcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom
Objectives: We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) treated on demand with recombinant von Willebrand factor (rVWF) in the United Kingdom. Methods: Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the on‐demand treatment of spontaneous/traumatic bleeds, or the prevention/treatment of surgical bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD‐related HCRU data associated with the on‐demand treatment of all recorded bleeds were collected at first (index) treatment, for 12 months pre‐index and 3–12 months post‐index. Results: Twelve patients (91.7% female and White/Caucasian, mean age 34.2 years) were treated on demand with rVWF at index: bleed resolution was achieved for all bleeds with limited requirement for additional treatments, no treatment switches, and no complications reported. Physician‐rated treatment satisfaction was ‘excellent’ (82.6%) or ‘good’ (17.4%) for all recorded on‐demand rVWF‐treated bleeds ( n = 23). Patients receiving any on‐demand treatment required an inpatient admission and ≥ 1 outpatient visit in 33.7% and 66.7% of cases, respectively. Conclusions: Results support the effectiveness and safety profile of on‐demand rVWF treatment for spontaneous/traumatic bleeds in adults with VWD, adding to the growing body of evidence for rVWF.